Evan Seigerman
Stock Analyst at BMO Capital
(3.77)
# 591
Out of 4,828 analysts
141
Total ratings
50%
Success rate
7.25%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $96 → $115 | $115.71 | -0.61% | 15 | May 6, 2025 | |
| BIIB Biogen | Maintains: Market Perform | $156 → $139 | $118.17 | +17.63% | 26 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $110 → $115 | $96.91 | +18.67% | 15 | Feb 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $566 → $520 | $424.99 | +22.36% | 14 | Dec 20, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $46.45 | +31.32% | 11 | Nov 12, 2024 | |
| INCY Incyte | Reiterates: Underperform | $48 → $52 | $58.98 | -11.83% | 12 | Oct 30, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,001 → $1,101 | $734.57 | +49.88% | 8 | Aug 9, 2024 | |
| IRON Disc Medicine | Reiterates: Outperform | $50 → $70 | $44.24 | +58.23% | 5 | Jun 17, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $25.57 | +56.43% | 1 | Feb 28, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $40 | $7.71 | +418.81% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $527.78 | +49.30% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $2.09 | +19.62% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $265.86 | -8.60% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $4.81 | +149.48% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $22.28 | +169.30% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $27 | $1.13 | +2,289.38% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.43 | +1,997.90% | 3 | May 12, 2020 |
Neurocrine Biosciences
May 6, 2025
Maintains: Market Perform
Price Target: $96 → $115
Current: $115.71
Upside: -0.61%
Biogen
Feb 13, 2025
Maintains: Market Perform
Price Target: $156 → $139
Current: $118.17
Upside: +17.63%
Gilead Sciences
Feb 12, 2025
Maintains: Outperform
Price Target: $110 → $115
Current: $96.91
Upside: +18.67%
Vertex Pharmaceuticals
Dec 20, 2024
Maintains: Outperform
Price Target: $566 → $520
Current: $424.99
Upside: +22.36%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $46.45
Upside: +31.32%
Incyte
Oct 30, 2024
Reiterates: Underperform
Price Target: $48 → $52
Current: $58.98
Upside: -11.83%
Eli Lilly and Company
Aug 9, 2024
Maintains: Outperform
Price Target: $1,001 → $1,101
Current: $734.57
Upside: +49.88%
Disc Medicine
Jun 17, 2024
Reiterates: Outperform
Price Target: $50 → $70
Current: $44.24
Upside: +58.23%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $25.57
Upside: +56.43%
Replimune Group
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $7.71
Upside: +418.81%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $527.78
Upside: +49.30%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $2.09
Upside: +19.62%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $265.86
Upside: -8.60%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $4.81
Upside: +149.48%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $22.28
Upside: +169.30%
Aug 13, 2021
Maintains: Outperform
Price Target: $30 → $27
Current: $1.13
Upside: +2,289.38%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.43
Upside: +1,997.90%